扶正化瘀胶囊对抗病毒有效的乙型肝炎肝硬化患者外周血细胞因子的调节  

The regulatory effect of Fuzhenghuayu capsule on peripheral blood cytokines in hepatitis B-related cirrhosis patients with effectively antiviral therapy

作　　者：吴眉[1] 徐列明[1] 

机构地区：[1]上海中医药大学附属曙光医院,上海中医药大学肝病研究所,201203

出　　处：《肝脏》2017年第12期1094-1097,共4页Chinese Hepatology

基　　金：上海中医药大学附属曙光医院四明青年基金(SGKJ-201718)

摘　　要：目的观察扶正化瘀胶囊对抗病毒有效的乙型肝炎肝硬化患者外周血细胞因子的分泌、肝功能及肝硬化程度的影响。方法收集恩替卡韦抗病毒治疗有效的乙型肝炎肝硬化患者63例,将其分为扶正化瘀组(FZHY组)30例,均用恩替卡韦联合扶正化瘀胶囊治疗;对照组33例,均单用恩替卡韦治疗;另选20名健康体检者作为健康对照组。治疗1年后分别观察乙型肝炎肝硬化患者肝硬化程度(肝硬度扫描,FibroScan),肝功能(ALT、AST、Alb、TBil)。比较3组外周血细胞因子(IL-1α、IL-1β、IL-4、IL-6、IL-8、IL-10、IL-13、MCP-1、INF-γ、TNF-α、TGF-β1)表达。结果较治疗前FZHY组患者ALT(36.00±19.74 vs 22.82±9.32)IU/L、AST(48.08±26.38 vs 34.47±17.14)IU/L显著下降(P<0.05,P<0.01)。FZHY组肝硬度有所下降(22.53±20.80 vs 14.28±10.40)kPa(P<0.05)。治疗后,FZHY组患者TGF-β1(1107.12±414.36 vs 512.24±219.36)pg/mL,IL-13(33.23±17.95 vs 13.58±17.93)pg/mL显著下降(P<0.01)。结论扶正化瘀胶囊可以减少炎性因子的分泌,从而抑制抗病毒有效的乙型肝炎肝硬化患者的进展。Objective To investigate the effect of Fuzhenghuayu（FZHY）capsule on peripheral blood cytokines secretion,liver function and liver cirrhosis in hepatitis B-related cirrhosis patients with effectively antiviral therapy.Methods A total of 63 patients with hepatitis B-related cirrhosis treated with entecavir effectively were enrolled in this study,including 30 cases treated with entecavir combined with FZHY as FZHY group and 33 cases treated with entecavir only as control group.Twenty healthy cases were set as normal group.Liver cirrhosis,liver function [alanine aminotransferase（ALT）,aspartate transaminase（AST）,albumin（Alb）,total bilirubin（TBiL）]and the secretion of peripheral blood cytokines interleukin（IL）-1α,IL-1β,IL-4,IL-6,IL-8,IL-10,IL-13,monocyte chemotactic protein（MCP）-1,interferon（IFN）-γ,tumor necrosis factor（TNF）-α,TGF-β1）were measured after one-year treatment,respectively.Results After treatment,the levels of ALT and AST decreased significantly in FZHY group（P〈0.05,P〈0.01）.Liver stiffness in FZHY group（P〈0.05）and control group were both decreased.Compared with that in control group,the levels of TGF-β1 and IL-13 declined significantly in FZHY group after treatment（P〈0.01）.Conclusion FZHY capsule could relieve the progress of liver cirrhosis in effectively antiviral patients through inhibiting the secretion of inflammatory cytokines.

关 键 词：扶正化瘀胶囊 乙型肝炎肝硬化 细胞因子 肝硬度扫描 

分 类 号：R512.62[医药卫生—内科学] R575.2[医药卫生—临床医学]